Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1Myeloproliferative Disorders 1Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 34Standard of Care 32Carboplatin 32Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Cisplatin 24Gemcitabine 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Oxaliplatin 18Docetaxel 18Rituximab 16Irinotecan 16Cetuximab 16Drug Therapy 15Doxorubicin 15dostarlimab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13Prednisone 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × ASTX029 × 1 year × Clear all
NCT03520075 2025-07-03

Study of ASTX029 in Subjects With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed
192 enrolled 56 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡